Navigation Links
Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
Date:11/6/2008

o Phase 3 development. A sufficiently positive result from any one of the trials could also lead to a Phase 3 decision for that specific indication.

Darapladib Demonstrates Promise in Phase 2; GSK Confirms Plan to Initiate Phase 3 Development

In September 2008, results of the Integrated Biomarkers and Imaging Study- 2 (IBIS-2) showed that the use of darapladib, in addition to standard of care treatment, prevented expansion of the necrotic core, a region within coronary plaque associated with a high risk of rupture. Preventing expansion of the necrotic core may reduce the risk of recurrent heart attack in patients with coronary heart disease. The results of the Phase 2 study were presented at the 2008 Congress of the European Study of Cardiology and simultaneously published in the American Heart Association's journal, Circulation.

In its third quarter results press release issued October 22, 2008, GSK said, "These data support our belief that Lp-PLA2 inhibition may be an important therapeutic target and we plan to begin Phase 3 clinical studies shortly." Darapladib was discovered by GSK based on HGS technology. HGS will receive a 10% royalty on worldwide sales of darapladib if it is commercialized, and has a 20% co-promotion option in North America and Europe.

Process Development and Manufacturing Alliance with Hospira will Enable HGS to Generate Revenue from Available Manufacturing Capacity

In September 2008, HGS entered into an exclusive agreement with Hospira, Inc., for manufacturing process development and commercial supply of select Hospira biopharmaceutical products. In addition to the partnership with Hospira, HGS entered into a marketing services agreement with Eden Biodesign Ltd. in August 2008, under which Eden Biodesign will assist HGS in identifying other clients interested in large-scale manufacturing and late-stage process development. The Hospira alliance and similar agreements have the potential to generate $30-60 mi
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
2. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
3. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
4. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
5. Human Pheromone Sciences, Inc. - Shareholder Update
6. The human brain minimizes energy expenditure and integrates gravity in to the action plan
7. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
8. Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs
9. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
10. Complete Genomics Launches, Becomes Worlds First Large-Scale Human Genome Sequencing Company
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Neurostimulation - A Global Market Perspective ,, http://www.reportlinker.com/p01642
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4
... Sept. 18 Ingenuity Systems, the,leading provider...cientific,literature and data, is pleased to annou... major public-private biomedical research,partners...biological,markers to support new drug development...he founding members of the Consortium include the ...
...er 18 - Clinical Study Demonstrates Breakthrough... Capacities and Expands Potential Production,Capac... Sanofi pasteur, the vaccines division of sanofi-...ts new investigational H5N1 pandemic influenza,vac...high immune response,at the lowest dose of H5N1 an...
...e University of Pennsylvania have developed nanowi...ears and retrieving that data a thousand times fas...Flash memory and micro-drives, all using less powe...tesh Agarwal, an assistant professor in the Depart...leagues developed a self-assembling nanowire of ge...
Other Biology Technology:Ingenuity Systems Joins Biomarkers Consortium 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3
(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
(Date:12/2/2009)PHILADELPHIA Exposure to secondhand smoke for a prolonged period of time and in high quantity may increase the risk of breast cancer, even in women who never smoked cigarettes themselves. , "The qu
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Increased nicotine levels detected in those who light-up earlier 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2The Wonder 28R 29 You Love Now Offers Even More of the Nutrition You Need Wonder Classic and Wonder Classic Sandwich Provide Even More Calcium and N 54290 1The Wonder 28R 29 You Love Now Offers Even More of the Nutrition You Need Wonder Classic and Wonder Classic Sandwich Provide Even More Calcium and N 54290 2Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 1Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 2Frost 26 Sullivan 3A Outsourcing Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 54286 3Midbrook Pushes for Innovation in Medical Decontamination 54284 1Midbrook Pushes for Innovation in Medical Decontamination 54284 2Midbrook Pushes for Innovation in Medical Decontamination 54284 3
... all recommended flu vaccine appear to be less lik...timates hospitalizes 20,000 children every year. ,...Pediatrics by the University of Rochester Medical...nths (the youngest able to receive the vaccine) an...y found that, even though those years had poor mat...
...ly cause human blood and plasma to clota process t...g the course of vertebrate evolution, according to...al Institute of Allergy and Infectious Diseases, a...be published online Nov. 2 in Nature Chemical Bio...derstanding of coagulation during bacterial infect...
... universities, and inventors designing and manufac...ted economy will radically change over the next de...growing fieldknown as bioelectronicsfrom nine expe...8, from 4:45-6 p.m., in room 202, of the Electrica...ren St, at the northwest corner of Summit and Warr...
Other Biology News:Flu shot protects kids -- even during years with a bad vaccine match 2Nature study demonstrates that bacterial clotting depends on clustering 2NJIT seminar set for Nov. 6 to focus on bioelectronics -- emerging research area 2
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100* from Molecular Probes (Invitrogen)
Feline IL-5, Unconjugated from R&D Systems
...ess Cloning Checker Kits provide two highly effici...ter transformation without time-consuming plasmid ...d in Kit I, all you need to do is to transfer part... transformation plates into the solutions provided...
Biology Products: